United Kingdom (UK)
Recombinant monoclonal antibody to E protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 14D5.
UniProt Accession Number of Target Protein: P14336
Alternative Name(s) of Target: tick-borne encephalitis virus; TBEV; envelope domain III; EDIII; envelope protein
Immunogen: The original antibody was generated by immunizing BALB/c mice with purified E protein.
Specificity: This antibody binds a neutralizing epitope localized in domain III of glycoprotein E of TBEV between residues 301–339. Tick-borne encephalitis virus (TBEV) is a member of the tick-borne flaviviruses (TBFVs) in the family Flaviviridae which cause encephalomeningitis and encephalitis in humans and other animals.
Application Notes: The specificity of the IgG1 format was confirmed by ELISA analysis. The antibody was able to neutralize infectivity of TBEV in vitro (Tsekhanovskaya et al. 1993; PMID: 7505512). Two chimeric versions of the antibody were constructed, ch14D5a and ch14D5b, the affinity constants of which were 2.6 × 10^10 M−1 and 1.0 × 10^7 M−1, respectively, as determined by surface plasmon resonance. The chimeric ch14D5a and parental antibodies were analyzed for the neutralizing activity against TBEV strain 205 by FRNT. The neutralization index (IC50) of the chimeric version was 0.04 µg/ml and 0.5 µg/ml for the parental version. In vivo experiments using the chimeric ch14D5a version resulted in a 100% survival of the mice infected with 240 LD50 of TBEV at a dose of 10 µg/mouse. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV (Baykov et al., 2014; PMID: 24837772). The antibody was employed for in vivo experiments in BALB/c mice infected with TBEV, at doses of 100 µg and 10 µg of antibody per mouse. The antibody showed protective efficacy when injected at the high dose one day after infection, with survival rates that were TBEV dose-dependent, and complete protection when it was injected one day before infection. No protection was observed in mice received the low dose of the antibody (Matveev et al., 2020; PMID: 32409136). The crystal structure of the Fab fragment of the chimeric antibody in complex with the D3 domain of TBEV glycoprotein E was determined (Baykov et al., 2021). The antibody detected the EIII protein by western blot analysis (Stenkova et al., 2017; PMID: 28741465). Immunofluorescence was performed on Vero E6 cells using this antibody (Levanov et al. 2014, PMID: 24371235).
Antibody first published in:
Tsekhanovskaya et al. Epitope analysis of tick-borne encephalitis (TBE) complex viruses using monoclonal antibodies to envelope glycoprotein of TBE virus (persulcatus subtype) Virus Res. 1993 Oct;30(1):1-16. PMID:7505512
Note on publication:
The paper describes the development of a panel antibodies specific to the E protein of TBEV.